EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $214,000 | -2.7% | 4,329 | 0.0% | 0.00% | – |
| Q4 2021 | $220,000 | -9.1% | 4,329 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $242,000 | +30.8% | 4,329 | 0.0% | 0.00% | – |
| Q2 2021 | $185,000 | +2.8% | 4,329 | 0.0% | 0.00% | – |
| Q1 2021 | $180,000 | -10.9% | 4,329 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $202,000 | +9.8% | 4,329 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $184,000 | -11.5% | 4,329 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $208,000 | +4.5% | 4,329 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $199,000 | -23.5% | 4,329 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $260,000 | -35.5% | 4,329 | -39.2% | 0.00% | 0.0% |
| Q3 2019 | $403,000 | +219.8% | 7,120 | +216.4% | 0.00% | – |
| Q2 2019 | $126,000 | +10.5% | 2,250 | 0.0% | 0.00% | – |
| Q1 2019 | $114,000 | +26.7% | 2,250 | 0.0% | 0.00% | – |
| Q4 2018 | $90,000 | -42.3% | 2,250 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $156,000 | – | 2,250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |